Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
cisatracurium (bis-cation) (as besylate) 201.0 mg/30 ml eqv cisatracurium
DCH AURIGA SINGAPORE
M03AC11
150 mg/30 ml
INJECTION, SOLUTION
cisatracurium (bis-cation) (as besylate) 201.0 mg/30 ml eqv cisatracurium 150 mg/30 ml
INTRAVENOUS
Prescription Only
GlaxoSmithKline Manufacturing S.p.A.
ACTIVE
2013-02-05
NIMBEX™ INJECTION 5 MG/2.5 ML NIMBEX™ FORTE INJECTION 150 MG/30 ML CISATRACURIUM QUALITATIVE AND QUANTITATIVE COMPOSITION _AMPOULES:_ A sterile solution containing cisatracurium (bis-cation) (as besylate) 6.7 mg per 2.5 ml equivalent to 5 mg cisatracurium per 2.5 ml, without an antimicrobial preservative, supplied in an ampoule. _VIALS: _ A sterile solution containing cisatracurium (bis-cation) (as besylate) 201.0 mg per 30 ml equivalent to 150 mg cisatracurium per 30 ml, without an antimicrobial preservative, supplied in a vial. PHARMACEUTICAL FORM Solution for injection or infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter. CLINICAL PARTICULARS INDICATIONS _NIMBEX _is an intermediate-duration, non-depolarising neuromuscular blocking agent for i.v. administration. _NIMBEX _is indicated for use during surgical and other procedures and in intensive care. It is used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU), to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. _NIMBEX _contains no antimicrobial preservative and is intended for single patient use. DOSAGE AND ADMINISTRATION As with other neuromuscular blocking agents, monitoring of neuromuscular function is recommended during the use of _NIMBEX_ in order to individualise dosage requirements. USE BY I.V. BOLUS INJECTION IN ADULTS TRACHEAL INTUBATION: The recommended intubation dose of _NIMBEX_ for adults is 0.15 mg/kg administered rapidly over 5 to 10 seconds. This dose produces good to excellent conditions for tracheal intubation 120 seconds following injection. Higher doses will shorten the time to onset of neuromuscular block. The following table summarises mean pharmacodynamic data when _NIMBEX _injection was administered at doses of 0.1 to 0.4 mg/kg to healthy adult patients during opio Read the complete document
NIMBEX™ INJECTION 2 MG/ML NIMBEX™ FORTE INJECTION 150 MG/30 ML CISATRACURIUM QUALITATIVE AND QUANTITATIVE COMPOSITION _AMPOULES:_ A sterile solution containing cisatracurium (bis-cation) (as besylate) 2.68 mg per mL equivalent to 2 mg cisatracurium per ml, without an antimicrobial preservative, supplied in an ampoule. _VIALS: _ A sterile solution containing cisatracurium (bis-cation) (as besylate) 201.0 mg per 30 mL equivalent to 150 mg cisatracurium per 30 ml, without an antimicrobial preservative, supplied in a vial. PHARMACEUTICAL FORM Solution for injection or infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter. CLINICAL PARTICULARS INDICATIONS _NIMBEX _is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous (i.v.) administration. _NIMBEX _is indicated for use during surgical and other procedures and in intensive care. It is used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU), to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. _NIMBEX _contains no antimicrobial preservative and is intended for single patient use. DOSAGE AND ADMINISTRATION As with other neuromuscular blocking agents, monitoring of neuromuscular function is recommended during the use of _NIMBEX_ in order to individualise dosage requirements. USE BY I.V. BOLUS INJECTION IN ADULTS TRACHEAL INTUBATION: The recommended intubation dose of _NIMBEX_ for adults is 0.15 mg/kg administered rapidly over 5 to 10 seconds. This dose produces good to excellent conditions for tracheal intubation 120 seconds following injection. Higher doses will shorten the time to onset of neuromuscular block. Table 1 summarises mean pharmacodynamic data when _NIMBEX _injection was administered at doses of 0.1 to 0.4 mg/kg to healthy adult patients during opioid (thiopentone/fentanyl/midazolam) or propofol anaesthesia. TABLE 1: MEAN PHARMACODYNAMIC DATA FOLLOWING A RANGE OF _NIMBEX _DOSES Initial Read the complete document